Low-Dose Intermittent Trimethoprim-Sulfamethoxazole for Prevention of Pneumocystis carinii Pneumonia in Patients With Human Immunodeficiency Virus Infection Academic Article Article uri icon


MeSH Major

  • Exercise
  • Feedback, Physiological
  • Hypoglycemia
  • beta-Endorphin


  • The important role of chemoprophylaxis for the prevention of Pneumocystis carinii pneumonia (PCP) in human immunodeficiency virus type 1 (HIV)-infected patients is undisputed. The most cost-effective regimen, however, is unknown. We reviewed our experience at two hospitals in the New York City area in which low-dose, intermittent therapy with the combination of trimethoprim and sulfamethoxazole was used to prevent PCP in HIV-infected patients. During a total of 202 months of primary prophylaxis in 32 patients and 319 months of secondary prophylaxis in 35 patients, PCP was diagnosed only once. More than 80% of patients were receiving zidovudine concomitantly. Adverse reactions to trimethoprim-sulfamethoxazole occurred in 31% and 52% of those receiving primary or secondary prophylaxis, respectively. When those patients who were considered ineligible to receive trimethoprim-sulfamethoxazole prophylaxis (principally based on a prior adverse drug reaction) are also factored in, then approximately 50% of HIV-infected patients are candidates for long-term trimethoprim-sulfamethoxazole prophylaxis. The projected cost savings of this prophylaxis regimen, compared with those currently recommended by the US Public Health Service, are enormous.

publication date

  • January 1991



  • Academic Article


Digital Object Identifier (DOI)

  • 10.1001/archinte.1991.00400040042010

PubMed ID

  • 1901482

Additional Document Info

start page

  • 688

end page

  • 92


  • 151


  • 4